IBIvan Bristow

Ivan Bristow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ivan Bristow has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Squamous Cell Carcinoma in the Diabetic Foot: A Review of Published Case Reports

    by Matthew R. Carroll, Ivan R. Bristow

    Introduction: Squamous cell carcinoma (SCC) is a malignant tumour arising from epidermal keratinocytes and is the second most common form of skin cancer globally. Although relatively rare on the foot, SCC and its variants may occur in people with diabetes and can mimic common diabetes‐related foot ulcerations. This diagnostic overlap presents a risk of delayed recognition and treatment. The aim of this review was to synthesise published case reports of SCC occurring in the diabetic foot and to describe patient characteristics, clinical presentation, and outcomes. Methods: A review of case reports was conducted in accordance with the PRISMA guidelines. Electronic databases (Medline, CINAHL, SPORTDiscus and SCOPUS) were searched up to September 2025 using relevant terms for SCC and its variants. Studies describing clinical cases of SCC arising on the foot in individuals with diabetes were included. Results: Thirty‐one cases from 13 countries were included. The mean age of patients was 62 years, with a predominance of males (71.0%) and type 2 diabetes (64.5%). Lesions most affected the right foot (64.5%) and were frequently located on the toes or plantar surfaces. The mean lesion duration prior to diagnosis was 61.9 months (range 2–360; n = 25). Initial misdiagnosis was most commonly as a foot ulcer (54.8%), followed by a wart (19.4%) and osteomyelitis (12.9%). Final diagnoses included SCC (51.7%), verrucous carcinoma (35.5%), and Marjolin's ulcer (12.9%). Pain was reported in 58.1% of cases despite neuropathy being present in 45.2%. Recurrence occurred in 16.1% of cases. Conclusions: Squamous cell carcinoma in people with diabetes‐related foot disease is rare but frequently misdiagnosed, resulting in prolonged lesion duration prior to diagnosis. Clinicians should maintain a high index of suspicion for malignancy in atypical or non‐healing foot lesions, particularly those with unusual features or persistence despite treatment. Early biopsy is essential for timely diagnosis and optimising outcomes.

  • British Association of Dermatologists guideline for managing fungal nail infection (onychomycosis) 2026

    by Mahreen Ameen, Neda Alband, Kashif Bhatti, David de Berker, Ivan Bristow, John T Lear, Angelika Razzaque, Malcolm Richardson, Jui Vyas, Amanda Roberts, et al.

    Lay Summary: Fungal nail infection (FNI) is a common condition. It affects the toenails and fingernails. Fungi grow in the nail, causing thickening, discoloration or crumbling. Around 1 in 2000 children have FNI. This increases to one in three people aged over 65 years. The British Association of Dermatologists brought together a group of experts on FNI. They included consultant dermatologists, pharmacists, podiatrists and people with lived experience of FNI. The group reviewed the published evidence on treatment. This UK-based group produced 44 recommendations. Management of most people with FNI is in primary care. However, more complex cases may need referral to a dermatologist. Accurate diagnosis is important. Treatment decisions should always fit the person with FNI. Factors include the type of infection, age, general health and personal preference. People with FNI should be told the benefits and risks of treatment and how long treatment will take. Nails may not always return to their previous appearance even when the infection is cured. Topical treatments are those applied to the affected nail. These may be suitable for mild infections or for people who cannot take oral medication. For many, an oral tablet called ‘terbinafine’ is the first-line treatment. When terbinafine is not suitable, other oral tablets called ‘itraconazole’ or ‘fluconazole’ can be used. Combination approaches may be helpful for stubborn infections. Children and young people can receive antifungal medicines. Doses should be adjusted according to their age and weight. The authors present a management pathway for patients with FNI. This will guide clinicians through the treatment options. Recommendations for future research are also included. Finally, audit points are presented. These will allow hospitals to check that the care of patients with FNI is meeting the right standards.

  • Open Access

    Podiatric Surgery in Australia: Evaluating the Impact of Title Change From ‘Podiatric Surgeon’ to ‘Surgical Podiatrist’

    by Alan Borthwick, Ivan Bristow, Susan Nancarrow

    In late 2025, the Australian Health Ministers Meeting formally announced a timeline for change of the protected specialist title ‘podiatric surgeon’, to be replaced with ‘surgical podiatrist’. This marks a significant adjustment, given the medical profession has long been opposed to the title and practice of podiatric surgery. This commentary discusses the change in context and evaluates the likely impact on podiatric surgery, considering the broader national state policy agenda.

  • Open Access

    Independent prescribing in the UK: insights from the Department of Health Allied Health Professions Medicines Project team

    by Ivan Bristow, Catherine Bowen, Nicky Wilson, Alan Borthwick

    Background: The UK medicines legislation was amended ten years ago (2013) to allow podiatrists and physiotherapists independent prescribing rights, the first of the allied health professions to do so. Non‐medical prescribing formed one part of a broader policy agenda promoting role flexibility in response to the challenge of an ageing population and the need to maintain effective health provision in the face of a contracting workforce.Aim: The aim of this study was to outline the experiences of the Department of Health AHP medicines project board team in working towards independent prescribing for podiatry and physiotherapy, with a particular focus on the challenges encountered.Methods: In depth, open‐ended interviews were conducted with eight of the core members of the project team, drawn from those individuals who served throughout the duration of the project (2010–2013). Included were the former Department of Health Chief and Deputy Chief Allied Health Professions Officers; the Department of Health Engagement and Communications Officer; representatives of the Health and Care Professions Council; the Medicines and Healthcare products Regulatory Agency; the Council of Deans of Health; the Royal College of Podiatry and the Chartered Society of Physiotherapy (The team also included the representative of the Allied Health Professions Federation. However, as that representative is also a researcher in this study, he has recused himself from any role as a participant.). Data were transcribed and subject to a thematic analysis.Results: A complex picture of the project emerged revealing a range of obstacles and challenges, including inter‐professional role boundary tensions and negative prior assumptions about the two professions. Success hinged upon the adoption of a dual strategy involving submission of a robust case of need focused on patient benefit coupled with the careful management of professional expectations. Underpinning theory from the sociology of the professions offers a supportive explanatory framework for understanding the relationships between the various stakeholders involved.Conclusions: Ultimately, success depended upon aligning the project aims with healthcare policy through a clear focus on patient benefit. Balancing competing professional and policy demands through a continual emphasis on improved patient care laid the foundations for future projects by other allied health professions.


  • Open Access

    The treatment of plantar warts using microwave—A review of 85 consecutive cases in the United States

    by Aditya K. Gupta, Tong Wang, Elizabeth A. Cooper, Robert M. Conenello, Ivan R. Bristow

    BackgroundPlantar warts (verrucae plantaris) are a common source of pain for patients and are often refractory to treatment. Previous work has shown a high clearance rate of verrucae using a surface-based microwave device (Swift & REG;). AimsTo assess the efficacy, defined as the complete visible clearance of warts, in patients with verrucae plantaris receiving microwave treatment. PatientsWe undertook a retrospective review and identified records of 85 patients who underwent a course of microwave treatment at a single US-based podiatry centre. Efficacy was analyzed on the basis on intention-to-treat. ResultsIn patients who received & GE;1 session there was a complete clearance rate of 60.0% (51/85) (intention-to-treat; 59 patients completed treatment, 26 lost to follow-up) and 86.4% (51/59) per treatment completion; no significant differences in clearance rates of children and adults were observed (61.0% [25/41] vs. 59.1% [26/44]). There were 31 patients who received three sessions of microwave therapy with a clearance rate of 71.0% (22/31) as per intention-to-treat (27 patients completed treatment, 4 lost to follow-up). An average of 2.3 sessions (SD: 1.1; range: 1-6) was required for the complete clearance of plantar warts. Complete clearance was also observed in some patients with recalcitrant warts following additional treatment sessions (42.9% [3/7]). A significant reduction in wart related pain was reported for all patients undergoing treatment. Some patients continued to report a reduced amount of pain post-therapy compared with pretherapy. ConclusionsMicrowave treatment of verrucae plantaris appears to be a safe and effective procedure.


  • Open Access

    Dermatophyte resistance – on the rise

    by Ivan R. Bristow, Lovleen Tina Joshi

    Dermatophytes are group of filamentous fungi which have adapted to living on the skin of humans and other animals. In the last decade, reports have emerged from Asia of new dermatophyte strains showing resistance to the commonly used antifungal agent terbinafine and others. The spread of these resistant strains has been noted in many other countries globally. Little is known about the mechanisms or management of this emerging problem. Urgent research and changes to current practice are required if the spread of the infection is to be contained and managed effectively.


  • Open Access

    Paediatric Cutaneous Warts and Verrucae: An Update

    by Ivan Bristow

    Cutaneous warts are common lesions in children caused by the Human Papilloma Virus (HPV) and for most lesions spontaneously resolve within months of the initial infection, regardless of treatment. The infection is most prevalent in the second decade of life affecting over 40% of children. Studies have demonstrated wart virus carriage on normal skin is higher in children with active lesions and family members. Subtypes HPV 2, HPV 27, HPV 57 and HPV 63 are particularly common in paediatric populations. Warts arising on the plantar surface of the foot (verrucae) can be particularly problematic owing to the location. They may interfere with daily activities causing pain and embarrassment. Plantar lesions have been shown to be more resistant to treatment than warts elsewhere on the skin. Systematic reviews and studies conducted over the last decade have demonstrated little evidence of innovation or effective improvements in treatment of recalcitrant lesions over the last 30 years. However, newer modalities such as immunotherapy (using injected vaccines) and hyperthermia using microwave treatment may hold promise in improving the treatment of these common and therapeutically frustrating lesions.


  • Open Access

    Post marketing surveillance for Microwave Treatment of Plantar and Common Warts in Adults

    by Ivan Bristow, Shailesh Joshi, Jonathan Williamson, Michael Ardern-Jones

    A handheld microwave device (Swift ® , Emblation Limited) has been licenced and available for clinical use since 2016 in the fields of podiatry and dermatology and has been extensively used in treating cutaneous warts. As part of post marketing surveillance by the manufacturer, an online 79-item survey was distributed to podiatry clinics in the United Kingdom with a Swift ® device. A total of 126 clinics responded (59.6%). 6998 adults (® microwave treatment of cutaneous warts. What is already known about this topic?: Microwave treatment has shown to be effective in the treatment of cutaneous warts. What does the study add?: This survey of clinics using SWIFT microwave treatments reports on the effectiveness and safety of the device in the treatment of 8506 adult patients with common and plantar warts. Responding user clinics reporting efficacy with good clearance rates and low levels of adverse events demonstrating microwave is a safe and effective treatment for plantar and common warts.


  • Open Access

    The mystery of the COVID toes – turning evidence‐based medicine on its head

    by Ivan R. Bristow, Alan M. Borthwick

    The recent and rapid emergence of COVID‐19 infection has led to a flood of publications describing all aspects of the disease and its presentation. The appearance of chilblain‐like lesions, in children and young adults has particularly caught the attention of healthcare professionals with an interest in the foot. With such a novel infection, demand for information is high at a time when evidence is scarce. Consequently, there has been a renaissance in the publication of case studies. This type of research, previously relegated from many mainstream journals, as a low level source of evidence, has permitted the rapid reporting, publication and dissemination of much needed clinical data which can be used as a foundation to inform further research and investigations about a new global infection.


  • Nail disorders

    by Rodney Peter Richard Dawber, Ivan Bristow, Warren Turner